Please login to the form below

Not currently logged in
Email:
Password:

ThromoboGenics appoints Thomas Clay as chairman of the board

He moves from his previous position as non-executive director

Thomas ClayBelgium-based biotech ThromboGenics has appointed non-executive director Thomas Clay as its new chairman of the board and succeeds Staf Van Reet, who retires.

Clay has been a non-executive director of ThromboGenics since 2011 when he replaced his father, Landon Clay.

He said: “I Am very honoured to be appointed as chairman of the board of ThromboGenics at a time when the company is starting to make excellent progress with its exciting pipeline of four novel therapies for treating diabetic eye disease.”

Clay is also vice-president of East Hill Management, a US-based investment company and serves as chairman and CEO of Golden Queen Mining and as a director of the Clay Mathematics Institute.

Patrik De Haes, chief executive officer of ThromboGenics, said: “I am delighted that Thomas has agreed to take on the role of chairman, his rich experience and deep understanding of ThromboGenics and life sciences in general will be invaluable for the company in achieving its objectives going forward.”

27th June 2017

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Hanson Zandi

Hanson Zandi is a Creative and Digital Healthcare Agency. We combine 30 years’ experience with the enthusiasm of a start-up...

Latest intelligence

Programmatic methodology and why you should be using it
What is it? How does it work? Why is everyone talking about it? By Richard Webb - Associate Director...
Can you survive without the blue dot?
Or has the digital world has replaced our brain...
Alzheimers incidence
A roadmap to the successful treatment of Alzheimer’s disease
Building on past research to learn more about the disease and how to treat it...

Infographics